BridgeMD
New treatment option for Advanced Renal Cell Carcinoma
Official title Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
ClinicalTrials.gov ID: NCT07239596
What this study is testing
What is SHR-8068；Adebrelimab ；Bevacizumab?
SHR-8068；Adebrelimab ；Bevacizumab is an investigational medicine, being studied as a potential treatment for advanced renal cell carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18 to 75 years old (including boundary values)
- Volunteer to participate in this clinical study and sign informed consent;
- ECOG score 0-1;
- Expected survival ≥3 months;
- Patients with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology;
You likely can't join if
- Have previously used or are currently using HIF inhibitors.
- Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks...
- Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such...
- Undergoing major surgical treatment within a certain period of time after the first administration of medication (excluding diagnosis) or expecting...
- There are severe gastrointestinal function abnormalities in clinical practice, which may affect the intake, transportation or absorption of drugs.
- Suffering from other active malignant tumors within 3 years or at the same time.
See the full eligibility criteria
- Age 18 to 75 years old (including boundary values)
- Volunteer to participate in this clinical study and sign informed consent;
- ECOG score 0-1;
- Expected survival ≥3 months;
- Patients with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology;
- Tumor tissue samples must be provided for testing
- There is at least one measurable or evaluable lesion that meets the RECIST 1.1 criteria;
- Adequate bone marrow and organ function.
- Have previously used or are currently using HIF inhibitors.
- Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks prior to the first administration of the study; Palliative radiotherapy...
- Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such vaccines will be needed during the treatment period.
- Undergoing major surgical treatment within a certain period of time after the first administration of medication (excluding diagnosis) or expecting major surgical treatment during the study period.
- There are severe gastrointestinal function abnormalities in clinical practice, which may affect the intake, transportation or absorption of drugs.
- Suffering from other active malignant tumors within 3 years or at the same time.
- Patients who have received organ transplants in the past (excluding corneal transplants).
- A clinically significant thrombotic or embolic event occurred within 6 months prior to the first administration of the drug.
- There are clinical symptoms or diseases of the heart that are not well controlled.
- Active tuberculosis.
- Moderate and severe ascites with clinical symptoms; Uncontrolled or moderate to excessive pleural effusion and pericardial effusion.
- The toxicity and/or complications of previous intervention measures have not been restored to the level of NCI-CTCAE≤1 or the inclusion and exclusion criteria.
- people with active hepatitis B or active hepatitis C.
- As determined by the researcher, there are other factors that may affect the research results or lead to the forced termination of this study midway
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.